Is there a cornucopia of returns in electroCore Inc. (ECOR) And Hepion Pharmaceuticals Inc. (HEPA)

electroCore Inc. (NASDAQ: ECOR) shares are 3.77% up in the year-to-date (YTD) period and have moved -6.78% or -$0.12 lower in the latest trading session. However, stock’s trailing 12-month performance remains nearly +415.46% lower. Comparatively, the stock is -50.00% down YTD and 77.51% over the trailing 3-month period. If we look at the shorter duration, its week performance is -14.51% and 3.77% over the month.

5 Stocks to make up the PERFECT 2021 gold portfolio

Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.

Click here to download your free report right away


Analyst Recommendations

On November 14, 2019, JMP Securities recommended the ECOR stock is a Mkt Perform, while earlier, BTIG Research had Upgrade the stock as a Buy on August 14, 2020. 4 analysts offering the recommendations for the stock have a consensus rating of 2.50 to suggest that the ECOR stock is a “Moderate Buy. 0 of the 4 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 3 recommend buying, with 0 rating it as an Overweight.

The stock currently trades at $1.65. The forecasts give the electroCore Inc. stock a price target range of $4.00 on the higher side while at least one analyst think the stock could plunge to a low of $3.00. The two limits represent an upside potential of 58.75% or 45.0%.

Earnings Forecast

Analysts estimate the earnings to increase 38.10% in the current quarter to -$0.13, up from the -$0.36 reported in the same quarter a year ago. For the current year, earnings should grow to an average of -$0.65, up 49.00% from -$1.54 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between -$0.17 and -$0.08. Wall Street estimates earnings per share to be at an average of -$0.47 for the next year.

Insider Transactions Summary

According to SEC data, total insider shares purchases at the company stands at 5 over the last 12 months, while SEC filings reveal that there have been 1 insider sales over the same period. Insiders have purchases 2,306,740 shares while those sold by company executives and officers stand at 1,156,494. The last 3 months have seen insiders trade a total of 0 and 0 in purchases and sales respectively.

Moody Trevor J, a Director at the company, bought 116,647 shares worth $99150.0 at $0.85 per share on Apr 14. The Director had earlier bought another 176,470 ECOR shares valued at $0.15 million on Apr 14. The shares were bought at $0.85 per share. TULLIS JAMES L L (Director) bought 1,764,705 shares at $0.85 per share on Apr 14 for a total of $1.5 million while TULLIS JAMES L L, (Director) bought 4,984 shares on Nov 22 for $7127.0 with each share fetching $1.43.

Hepion Pharmaceuticals Inc. (NASDAQ:HEPA), on the other hand, is trading around $3.53 with a market cap of $31.63M and analyst research firms have a positive stance on its shares. Some analysts are even forecasting -$1.51 per share in earnings this year on a short term (1 year) basis.

Let us briefly look at the Hepion Pharmaceuticals Inc. (HEPA) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.

Company balance sheet and cash flow

HEPA’s operating expenses over the recent quarter were at $69000.0. This represented a 101.45% of the company’s total revenues which amounted $4.78 million. With this in place, we can see that the company’s diluted EPS declined -$0.58 on the year-over-year period, shrinking to -$7.48 as given in the last earnings report.

In terms of the balance sheet & cash flow as of (Sep 2020), the total assets figure advanced to $24.08 million from $23.27 million over the previous quarter. The cash flow from operating activities totaled -$7.79 million, significantly lower than the -$3.32 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$7.8 million.

Insider activity

Insiders have transacted a total of 0 times at Hepion Pharmaceuticals Inc. over the last 6 months, with insider purchases undertaken 0 times and accounting for 0 shares. Insider sales totaled 0 shares over the same period, with these deals completed in 0 transactions. Looking at these numbers, we realize that net purchases over that period are 0.0 shares. Insiders now hold a total of 148.46k shares after the latest sales, with 0.00% net shares purchased.

Major holders

Insiders own 1.64% of the company shares, while shares held by institutions stand at 3.60% with a share float percentage of 6.07M. Investors are also buoyed by the number of investors in a company, with Hepion Pharmaceuticals Inc. having a total of 24 institutions that hold shares in the company.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free